Potential of RAS inhibition to improve metabolic bone disorders

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Gebru, Yoseph ^a   Diao, Teng Yue ^a   Pan, Hai ^a   Mukwaya, Emmanuel ^a   Zhang, Yan ^a,b  

^a UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CANDESARTAN; CORE BINDING FACTOR; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; OSTEOCLAST DIFFERENTIATION FACTOR; RENIN INHIBITOR; TELMISARTAN; VALSARTAN;

APOPTOSIS; BONE DEVELOPMENT; BONE DISEASE; BONE MARROW CELL; BONE MASS; BONE METABOLISM; BONE REMODELING; CELL DIFFERENTIATION; CELL REGENERATION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FRACTURE; HEMATOPOIESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; PLASMA HALF LIFE; RENAL OSTEODYSTROPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; BIOLOGICAL MODEL; BONE; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; BONE DISEASES, METABOLIC; DRUG EFFECTS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BONE AND BONES; BONE DISEASES, METABOLIC; HUMANS; MODELS, BIOLOGICAL; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84881488218     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/932691     Document Type: Review

References (44)

1. Ralston S. H., De Crombrugghe B., Genetic regulation of bone mass and susceptibility to osteoporosis. Genes and Development 2006 20 18 2492 2506 2-s2.0-33748680524 10.1101/gad.1449506 (Pubitemid 44396835)
2. Siamopoulos K. C., Kalaitzidis R. G., Inhibition of the renin-angiotensin system and chronic kidney disease. International Urology and Nephrology 2008 40 4 1015 1025 2-s2.0-56349108016 10.1007/s11255-008-9424-x
3. Nakagami H., Morishita R., Hormones and osteoporosis update. Effect of angiotensin II on bone metabolism. Clinical Calcium 2009 19 7 997 1002 2-s2.0-70350507732
4. Zhang Y., Diao T. Y., Gu S. S., Wu S. Y., Gebru Y. A., Chen X., Wang J. Y., Ran S., Wong M. S., Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin. Journal of the Renin-Angiotensin-Aldosterone System 2013 10.1177/1470320312471229
5. Haznedarolu I. C., Tuncer S., Gürsoy M., A local renin-angiotensin system in the bone marrow. Medical Hypotheses 1996 46 6 507 510 2-s2.0-0029883368 10.1016/S0306-9877(96)90122-X (Pubitemid 26184769)
6. Guan X. X., Zhou Y., Li J. Y., Reciprocal roles of angiotensin II and angiotensin II receptors blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis. International Journal of Molecular Sciences 2011 12 7 4206 4213 2-s2.0-79960800979 10.3390/ijms12074206
7. Hagiwara H., Hiruma Y., Inoue A., Yamaguchi A., Hirose S., Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. Journal of Endocrinology 1998 156 3 543 550 2-s2.0-0031952361 10.1677/joe.0.1560543 (Pubitemid 28131472)
8. Teitelbaum S. L., Bone resorption by osteoclasts. Science 2000 289 5484 1504 1508 2-s2.0-0034284970 10.1126/science.289.5484.1504
9. Lin I. C., Smartt J. M. Jr., Nah H., Ischiropoulos H., Kirschner R. E., Nitric oxide stimulates proliferation and differentiation of fetal calvarial osteoblasts and dural cells. Plastic and Reconstructive Surgery 2008 121 5 1554 1566 2-s2.0-43149100335 10.1097/PRS.0b013e31816c3bd7 (Pubitemid 351642705)
10. Shimizu H., Nakagami H., Osako M. K., Hanayama R., Kunugiza Y., Kizawa T., Tomita T., Yoshikawa H., Ogihara T., Morishita R., Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB Journal 2008 22 7 2465 2475 2-s2.0-46749101660 10.1096/fj.07-098954 (Pubitemid 351948664)
11. Kaneko K., Ito M., Fumoto T., Fukuhara R., Ishida J., Fukamizu A., Ikeda K., Physiological function of the angiotensin AT1a receptor in bone remodeling. Journal of Bone and Mineral Research 2011 26 12 2959 2966 2-s2.0-81855193731 10.1002/jbmr.501
12. Beyazit Y., Aksu S., Haznedaroglu I. C., Kekilli M., Misirlioglu M., Tuncer S., Karakaya J., Koca E., Buyukasik Y., Sayinalp N., Goker H., Ozcebe O. I., Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. Journal of the National Medical Association 2007 99 1 57 63 2-s2.0-33846590649 (Pubitemid 46183959)
13. Franceschi R. T., The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment. Critical Reviews in Oral Biology and Medicine 1999 10 1 40 57 2-s2.0-0032737614 (Pubitemid 29510046)
14. Beyazit Y., Purnak T., Guven G. S., Haznedaroglu I. C., Local bone marrow renin-angiotensin system and atherosclerosis. Cardiology Research and Practice 2011 1 1 10 2-s2.0-79959381319 10.4061/2011/714515 714515
15. Asaba Y., Ito M., Fumoto T., Watanabe K., Fukuhara R., Takeshita S., Nimura Y., Ishida J., Fukamizu A., Ikeda K., Activation of renin-angiotensin system induces osteoporosis independently of hypertension. Journal of Bone and Mineral Research 2009 24 2 241 250 2-s2.0-58649096984 10.1359/jbmr.081006
16. Strawn W. B., Richmond R. S., Tallant E. A., Gallagher P. E., Ferrario C. M., Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. British Journal of Haematology 2004 126 1 120 126 2-s2.0-3042748331 10.1111/j.1365-2141.2004.04998.x (Pubitemid 38859492)
17. Gu S. S., Zhang Y., Li X. L., Wu S. Y., Diao T. Y., Hai R., Deng H. W., Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice. Bioscience, Biotechnology, and Biochemistry 2012 76 7 1367 1371 10.1271/bbb.120123
18. Gu S. S., Zhang Y., Wu S. Y., Diao T. Y., Gebru Y. A., Deng H. W., Early molecular responses of bone to obstructive nephropathy induced by unilateral ureteral obstruction in mice. Nephrology 2012 17 8 767 773 10.1111/j.1440-1797. 2012.01656.x
19. Lynn H., Kwok T., Wong S. Y. S., Woo J., Leung P. C., Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006 38 4 584 588 2-s2.0-33644979330 10.1016/j.bone.2005.09.011
20. Komers R., Renin inhibition in the treatment of diabetic kidney disease. Clinical Science 2013 124 553 566 10.1042/CS20120468
21. Lamparter S., Kling L., Schrader M., Ziegler R., Pfeilschifter J., Effects of angiotensin II on bone cells in vitro. Journal of Cellular Physiology 1998 175 1 89 98 (Pubitemid 28101975)
22. Hatton R., Stimpel M., Chambers T. J., Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. Journal of Endocrinology 1997 152 1 5 10 2-s2.0-0031013091 (Pubitemid 27026382)
23. Izu Y., Mizoguchi F., Kawamata A., Hayata T., Nakamoto T., Nakashima K., Inagami T., Ezura Y., Noda M., Angiotensin II type 2 receptor blockade increases bone mass. Journal of Biological Chemistry 2009 284 8 4857 4864 2-s2.0-64149118080 10.1074/jbc.M807610200
24. Zhang Y., Wang Y., Chen Y., Deb D. K., Sun T., Zhao Q., Li Y. C., Inhibition of renin activity by aliskiren ameliorates diabetic nephropathy in type 1 diabetes mouse model. Journal of Diabetes Mellitus 2012 2 3 353 360 10.4236/jdm.2012.23055
25. Pimenta E., Oparil S., Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vascular Health and Risk Management 2009 5 453 463 2-s2.0-67449100772
26. Azizi M., Webb R., Nussberger J., Hollenberg N. K., Renin inhibition with aliskiren: where are we now, and where are we going? Journal of Hypertension 2006 24 2 243 256 2-s2.0-33644789557 10.1097/01.hjh.0000202812.72341.99 (Pubitemid 43348229)
27. Kwok T., Leung J., Zhang Y. F., Bauer D., Ensrud K. E., Barrett-Connor E., Leung P. C., Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporosis International 2012 23 8 2159 2167 2-s2.0-80755141411 10.1007/s00198-011-1831-7
28. Nakagami H., Osako M. K., Morishita R., Potential effect of angiotensin II receptor blockade in adipose tissue and bone. Current Pharmaceutical Design 2013 19 17 3049 3053 10.2174/1381612811319170011
29. Stucchi P., Cano V., Ruiz-Gayo M., Fernández-Alfonso M. S., Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. British Journal of Pharmacology 2009 158 3 771 778 2-s2.0-70350057468 10.1111/j.1476-5381.2009.00355.x
30. Moser M., Izzo J. L. Jr., Sica D. A., The use of renin inhibitors in the management of hypertension. Journal of Clinical Hypertension 2007 9 9 701 705 2-s2.0-38349032511 10.1111/j.1524-6175.2007.07316.x
31. Brown M. J., Direct renin inhibition-a new way of targeting the renin system. Journal of the Renin-Angiotensin-Aldosterone System 2006 7 2 S7 S11 2-s2.0-33847704535 (Pubitemid 46380764)
32. Stanton A., Jensen C., Nussberger J., OBrien E., Blood Pressure Lowering in Essential Hypertension with an Oral Renin Inhibitor, Aliskiren. Hypertension 2003 42 6 1137 1143 2-s2.0-0347479295 10.1161/01.HYP.0000101688.17370.87 (Pubitemid 37549068)
33. Rahuel J., Rasetti V., Maibaum J., Rüeger H., Göschke R., Cohen N.-C., Stutz S., Cumin F., Fuhrer W., Wood J., Grütter M. G., Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chemistry and Biology 2000 7 7 493 504 2-s2.0-0033941893 10.1016/S1074-5521(00)00134-4 (Pubitemid 30466984)
34. Brown M. J., Aliskiren. Circulation 2008 118 7 773 784 2-s2.0-50349094508 10.1161/CIRCULATIONAHA.108.787630
35. Wood J. M., Maibaum J., Rahuel J., Grütter M. G., Cohen N., Rasetti V., Rüger H., Göschke R., Stutz S., Fuhrer W., Schilling W., Rigollier P., Yamaguchi Y., Cumin F., Baum H., Schnell C. R., Herold P., Mah R., Jensen C., O'Brien E., Stanton A., Bedigian M. P., Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications 2003 308 4 698 705 2-s2.0-0042661157 10.1016/S0006-291X(03)01451- 7 (Pubitemid 36976519)
36. Limoges D., Dieterich H. A., Yeh C.-M., Vaidyanathan S., Howard D., Dole W. P., A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics 2008 46 5 252 258 2-s2.0-43449133877 (Pubitemid 351663162)
37. Brown N. J., Vaughan D. E., Angiotensin-converting enzyme inhibitors. Circulation 1998 97 14 1411 1420 2-s2.0-0032515917 (Pubitemid 28182680)
38. Morishita R., Higaki J., Nagano M., Nakamura F., Tomita N., Zhao Y., Mikami H., Miyazaki M., Ogihara T., Discrepancy between renin mRNA and plasma renin level in angiotensin-converting enzyme inhibitor-treated rats. Clinical and Experimental Pharmacology and Physiology 1993 20 1 15 20 2-s2.0-0027396416 (Pubitemid 23015727)
39. Barreras A., Gurk-Turner C., Angiotensin II receptor blockers. Proceedings (Baylor University. Medical Center) 2003 16 1 123 126
40. Burnier M., Angiotensin II type 1 receptor blockers. Circulation 2001 103 6 904 912 2-s2.0-0035852724 (Pubitemid 32163892)
41. Krause M. W., Fonseca V. A., Shah S. V., Combination inhibition of the renin-angiotensin system: is more better. Kidney International 2011 80 3 245 255 2-s2.0-79960392722 10.1038/ki.2011.142
42. Albayrak M., Celebi H., Albayrak A., Sayilir A., Yesil Y., Balcik O. S., Yokus O., Celik T., Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma. Journal of the Renin-Angiotensin-Aldosterone System 2012 13 2 259 264 10.1177/1470320312437070
43. Durik M., Sevá Pessôa B., Roks A. J., The renin-angiotensin system, bone marrow and progenitor cells. Clinical Science 2012 123 205 223 10.1042/CS20110660
44. Haznedaroglu I. C., Beyazit Y., Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clinical Science 2013 124 307 323 10.1042/CS20120300